During outbreaks of respiratory infections, we all wear face masks to protect ourselves against viruses and bacteria inhaled through the nose or introduced into the body through the mouth cavity. However, our lungs are not sterile in the first place. Just like the intestine, they have their own microbiota. But if some imbalance occurs in it (e.g., from smoking, use of antibiotics or weaker immunity), the pathogenic germs that we “catch” become especially active. Today, an increasing amount of data give evidence that microbial communities of the intestine and the lungs are closely connected, and the use of certain probiotics not only helps restore the balance in the intestinal microbiota but that of the lungs, too, and, on top of that, protects against respiratory infections1. Based on most recent Western research in that area, ORVIS Probiotic by Evalar was developed, the first probiotic in Russia2 to keep airways of adults and children of the age 3+ good and healthy**.

Naturally, you might want to know how the presence of a probiotic in the intestine can affect our respiratory system. To begin with, let us recall that beneficial intestinal microbiota is directly involved in boosting immunity. If there are some troubles with that microbiota for any reason, the body’s defenses, including those of respiratory organs, get weaker. In that case, as it was stated above, pathogenic bacteria and viruses in the lungs can dominate other agents of the microbiota, and infection becomes inevitable.

However, as it turned out, it is just one mechanism of interaction between microbial communities of the intestine and the lungs. According to one theory, beneficial bacteria in the intestine excrete special substances that not only can “govern” immunity but, as they get into the blood stream, they take part in controlling the composition of the pulmonary microbiota in such a way that protection against harmful viruses and bacteria remains strong as ever.

That knowledge triggered a conclusion that specially selected probiotics can contribute to the protection of the respiratory system against infections1. Probiotics developed on the basis of beneficial lactic bacteria of a special strain, Lactobacillus plantarum DR7, have good potential in that respect3.

Each capsule of the newly released product, ORVIS Probiotic by Evalar, contains 1 billion* probiotic organisms of that kind, Lactobacillus plantarum DR7, which help keep up the normal function of the airways**.

Moreover, ORVIS Probiotic helps suppress growth of pathogenic microbiota, including S. aureus**. It is a common cause of infections, and an estimated 40% of the human population are long-term carriers of S. aureus4. The nasal cavity is one of the most important sites of the harmful bacteria colonization in humans.

And, of course, ORVIS Probiotic helps keep up the balance of the human gastrointestinal microbiota and the immunity at large**.

The product was created with high quality raw materials manufactured by a Spanish producer (AB-BIOTICS, S.A., Barcelona), and does not contain titanium dioxide.

The new product is very easy and convenient to use: One capsule a day is quite enough! If necessary, empty the capsule contents into a cup of water or milk of room temperature, stir, and drink at once**.

You can buy unique2 ORVIS Probiotic at pharmacies of the Evalar pharmacy chain or at other pharmacies across the country, or at Fitomarket, Evalar’s official marketplace of healthy lifestyles!

* The information was supplied by the substance manufacturer.

** Confirmed by Registration Certificate No. AM. dated May 14, 2020.

1 Zakharova I.N., Kasyanova A.N., Klimov L.Ya. et al. The Microbiome of the Respiratory Tract: Knowledge Update. Pediatrics (supplement to the Consilium Medicum journal), 2018; 4: 10-17. [in Russian]

2 According to the state registry of registered dietary supplements (http://fp/, as of October 14, 2020.

3 Chong H. el al. Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. J Dairy Sci. 2019 Jun; 102 (6): 4783-4797.

4 Litusov N.V. Gram-positive aerobic cocci: An illustrated textbook. Yekaterinburg: Ural State Medical University Publishers, 2016. P. 23. [In Russian]